Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. The company is headquartered in San Diego, California.
IPO Year: 2004
Exchange: NASDAQ
Website: oncternal.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/24/2022 | $5.00 | Buy | BTIG |
| 2/24/2022 | $50.00 | Buy | BTIG |
8-K - Oncternal Therapeutics, Inc. (0001260990) (Filer)
8-K - Oncternal Therapeutics, Inc. (0001260990) (Filer)
10-Q - Oncternal Therapeutics, Inc. (0001260990) (Filer)
8-K - Oncternal Therapeutics, Inc. (0001260990) (Filer)
10-Q - Oncternal Therapeutics, Inc. (0001260990) (Filer)
8-K - Oncternal Therapeutics, Inc. (0001260990) (Filer)
8-K - Oncternal Therapeutics, Inc. (0001260990) (Filer)
10-Q - Oncternal Therapeutics, Inc. (0001260990) (Filer)
8-K - Oncternal Therapeutics, Inc. (0001260990) (Filer)
EFFECT - Oncternal Therapeutics, Inc. (0001260990) (Filer)
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
The company reached consensus with the FDA on the design and major details of the Phase 3 superiority Study ZILO-301, to treat patients with relapsed or refractory MCL with zilovertamab plus ibrutinibThe FDA also provided positive feedback on the proposed key clinical and regulatory requirements of Oncternal's development program for zilovertamab in MCLGlobal registrational Study ZILO-301 is expected to be initiated in the second quarter of 2022Oncternal Therapeutics will host a conference call today at 4:30 p.m. ET to provide further details SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the d
Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT) (the "Company") today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission on March 17, 2025, which will remove Oncternal's securities from listing and registration on Nasdaq, and to subsequently deregister with the Securities and Exchange Commission ("SEC"). Nasdaq previously suspended the trading of Oncternal's common stock on December 3, 2024 and notified Oncternal that a Form 25 would be filed. However, as Nasdaq has not yet made the filing, Oncternal is doing so voluntarily to permit Oncternal to file a Form 15 to deregister with the SEC.
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT) (the "Company") today announced updated data from its Phase 1/2 Study of ONCT-534 for the treatment of patients with relapsed or refractory metastatic Castration-Resistant Prostate Cancer (mCRPC). Based on initial pharmacokinetic results, two additional dosing cohorts with twice daily (BID) oral dosing of ONCT-534 had been incorporated in the Phase 1/2 study ONCT-534-101 (NCT05917470). Overall, fifteen patients received ONCT-534 once daily (QD) in six dosing cohorts and six patients received ONCT-534 BID in two dosing cohorts. Based on a data cut off of September 30, 2024, the BID dosing schedule was w
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT) (the "Company") today announced its decision to discontinue its clinical trials evaluating ONCT-534, its dual action androgen receptor inhibitor for the treatment of patients with metastatic castration resistant cancer, and ONCT-808, its ROR1-targeting autologous CAR T program for the treatment of patients with aggressive B-cell lymphoma, and to explore strategic alternatives. In the current study, interim Phase 1 results of ONCT-534 did not show clinically meaningful improvements of disease, including prostate-specific antigen (PSA) levels, in the 20 patients treated in eight dosing cohorts with vari
No dose-limiting toxicities or concerning side effects in our Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors; 1200 mg cohort for ONCT-534 given orally once daily enrolled and treated; initial data readout expected in the third quarter of 2024Phase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for patients with relapsed or refractory aggressive B-cell lymphoma is open and enrolling patients; clinical data update expected in the fourth quarter of 2024Cash, cash equivalents and short-term investments totaled $21.4 million
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2024 financial results after the U.S. financial markets close on Thursday, August 8, 2024. Oncternal's management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company's financial results. The live webcast of the call will be available online at investor.oncternal.com and will be archived there for at least 30 days. About Oncternal TherapeuticsOncternal Therapeutics is a clinical-stage biopharmaceutical
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the sixth dose cohort of its Phase 1/2 study of ONCT-534 for the treatment of patients with metastatic castration-resistant prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). Patients in the sixth cohort are receiving ONCT-534, the company's dual-action androgen receptor inhibitor (DAARI), at a dose of 1200 mg taken orally once each day. The decision to proceed to this higher do
SAN DIEGO, July 11, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D, Ph.D., Oncternal's President and Chief Executive Officer will present at the JonesTrading Healthcare Seaside Summit being held July 14-16, 2024 in San Diego, California. JonesTrading Healthcare Seaside SummitPresentation Date and Time: Monday, July 15, 2024 at 2:30pm PTWebcast Registration: Link Please contact your JonesTrading institutional salesperson to participate in the event. Links to the replay will be accessible on the Events & Presentations page of th
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the fifth dose cohort of its Phase 1/2 study of ONCT-534 for the treatment of patients with metastatic castration-resistant prostate cancer who are relapsed or refractory to approved androgen receptor pathway inhibitors (ARPI). Patients in the fifth cohort are receiving ONCT-534, the company's dual-action androgen receptor inhibitor (DAARI), at a dose of 600 mg taken orally once each day. The decision to proceed to this higher dose
Fourth dosing cohort at 300 mg per day is fully enrolled for the Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors; initial data readout expected in the latter part of the second quarterPhase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for patients with relapsed or refractory aggressive B-cell lymphoma, including patients that have failed prior CD19 CAR T treatment is open and enrolling patients; clinical data update expected in mid-2024Cash, cash equivalents and short-term investments totaled $27.0 million as of March 3
Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Anne C. Hansen, who is joining Oncternal as Senior Director, Clinical Data Management. The award will be made on May 1, 2024 under Oncternal's 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company. The award will consist of an option to purchase 5,000 shares of Oncternal common stock. The option will have a 10-year term
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will participate in a virtual fireside chat on the Treatment Landscape & New Treatment Options for Prostate Cancer. Oncternal's President and CEO, James Breitmeyer, M.D., Ph.D. will join Oppenheimer Senior Research Biotech Analyst, Hartaj Singh and a prostate cancer Key Opinion Leader on Tuesday, March 19th, 2024 at 11:00 AM ET. Dr. Breitmeyer will discuss the development of Oncternal's novel dual-acting androgen receptor inhibitor, ONCT-534, the ongoing Phase 1/2 clinical trial ONC
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Damien Bresson, who is joining Oncternal as Senior Director, Preclinical and Translation Science. The award will be made on February 1, 2024 under Oncternal's 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company. The award will consist of an option to purchase 4,500 shares of Oncternal common stock. The option will have a
SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Rebecca Nolan-Olson, who is joining Oncternal as Safety Manager. The award will be made on January 2, 2024 under Oncternal's 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company. The award will consist of an option to purchase 19,500 shares of Oncternal common stock. The option will have a 10-year term and an exercise pric
SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Jill DeSimone to its board of directors. "We are thrilled to have Jill join the Oncternal board of directors. Jill's accomplishments building a multi-billion dollar oncology business in the U.S. are a great fit for supporting Oncternal's transition into a late-stage oncology company," said James Breitmeyer, M.D., Ph.D., Oncternal's President and CEO. "As we embark into our first global Phase 3 registrational study Zilo-301, we will greatly benefit from her guidance to h
SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Steven Hamburger, Ph.D. as Senior Vice President of Regulatory Affairs and Quality Assurance. Dr. Hamburger brings over 35 years of global drug development experience leading to numerous marketing authorizations in oncology, rare diseases and other therapeutic areas, across multiple geographies. Most recently, Steve was responsible for clinical regulatory affairs at FerGene and was Vice President and Head, Regulatory Affairs at Checkmate Pharmaceuticals, and Regulatory
SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Pablo Urbaneja as Senior Vice President, Corporate Development. Mr. Urbaneja will be responsible for strategic planning and advancing corporate and business development initiatives at Oncternal. Most recently he served as Vice President, Corporate Development at Coherus Biosciences, where he helped transform its biosimilars and immuno-oncology late-stage pipeline. Previously, Mr. Urbaneja was in the pharmaceuticals and medical products practice of McKinsey & Company, wh
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of industry veteran Salim Yazji, M.D., as Chief Medical Officer. "Salim brings a wealth of relevant experience to Oncternal during this exciting time as we begin to advance our pipeline toward the registrational phase," said James Breitmeyer, M.D., Ph.D., Oncternal's President and CEO. "We believe that his extensive background in oncology drug development and strategy, experience with global regulatory authorities, and proven leadership ability make him an ideal fit for O
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Chase Leavitt as General Counsel. Mr. Leavitt joins the Company with extensive experience providing strategic, transactional, financial, and operational advice to life sciences companies. "Chase is a highly seasoned and pragmatic General Counsel and business leader with a broad background spanning both biotech and technology companies that will help to position Oncternal for our next stage of growth," said James Breitmeyer, M.D., Ph.D., Oncternal's President and CEO.
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
4 - Oncternal Therapeutics, Inc. (0001260990) (Issuer)
BTIG initiated coverage of Oncternal Therapeutics with a rating of Buy and set a new price target of $5.00
BTIG initiated coverage of Oncternal Therapeutics with a rating of Buy and set a new price target of $50.00
Oppenheimer initiated coverage of Oncternal Therapeutics with a rating of Outperform and set a new price target of $14.00
Brookline Capital initiated coverage of Oncternal Therapeutics with a rating of Buy and set a new price target of $16.00
HC Wainwright & Co. reiterated coverage of Oncternal Therapeutics with a rating of Buy and set a new price target of $9.00 from $8.00 previously
Northland Capital initiated coverage of Oncternal Therapeutics with a rating of Outperform and set a new price target of $21.00
SC 13G/A - Oncternal Therapeutics, Inc. (0001260990) (Subject)
SC 13G/A - Oncternal Therapeutics, Inc. (0001260990) (Subject)